Zhaoke Ophthalmology FY2025; revenue drops to CNY 32 million due to lower one-off license income

Reuters

昨天

Zhaoke Ophthalmology FY2025; revenue drops to CNY 32 million due to lower one-off license income

Zhaoke Ophthalmology reported regulatory milestones that could expand its near-term commercial portfolio, led by three flagship assets positioned for large ophthalmology markets in China and internationally.
In China, 國家藥監局 accepted the biological products license application for 貝伐單抗玻璃體腔內注射液 (TAB014), supporting a potential first-mover position in a wAMD-focused bevacizumab filing.
For 硫酸阿托品滴眼液 (NVK002), 國家藥監局 accepted the simplified new drug application for the 0.01% dose and accepted the new drug application for the 0.02% dose, keeping both formulations under review as potential growth drivers.
In the US, FDA approved the new drug investigational application for 環孢素眼用凝膠 to start a Phase III trial, which could strengthen partnering options and broaden the addressable market beyond Greater China.
Commercial readiness was supported by RMB 959 million in cash and cash equivalents, while loss narrowed to RMB 209 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhaoke Ophthalmology Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260325-12067098), on March 25, 2026, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2622078184"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622078184\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622078184?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-25 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622078184","market":"fut","top_or_hot":-1,"title":"Zhaoke Ophthalmology FY2025; revenue drops to CNY 32 million due to lower one-off license income","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zhaoke Ophthalmology FY2025; revenue drops to CNY 32 million due to lower one-off license income\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Zhaoke Ophthalmology reported regulatory milestones that could expand its near-term commercial portfolio, led by three flagship assets positioned for large ophthalmology markets in China and internationally.\n        </li>\n<li>\n          In China, 國家藥監局 accepted the biological products license application for 貝伐單抗玻璃體腔內注射液 (TAB014), supporting a potential first-mover position in a wAMD-focused bevacizumab filing.\n        </li>\n<li>\n          For 硫酸阿托品滴眼液 (NVK002), 國家藥監局 accepted the simplified new drug application for the 0.01% dose and accepted the new drug application for the 0.02% dose, keeping both formulations under review as potential growth drivers.\n        </li>\n<li>\n          In the US, FDA approved the new drug investigational application for 環孢素眼用凝膠 to start a Phase III trial, which could strengthen partnering options and broaden the addressable market beyond Greater China.\n        </li>\n<li>\n          Commercial readiness was supported by RMB 959 million in cash and cash equivalents, while loss narrowed to RMB 209 million.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhaoke Ophthalmology Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260325-12067098), on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhaoke Ophthalmology FY2025; revenue drops to CNY 32 million due to lower one-off license income</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhaoke Ophthalmology FY2025; revenue drops to CNY 32 million due to lower one-off license income\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-03-25 19:43</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zhaoke Ophthalmology FY2025; revenue drops to CNY 32 million due to lower one-off license income\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Zhaoke Ophthalmology reported regulatory milestones that could expand its near-term commercial portfolio, led by three flagship assets positioned for large ophthalmology markets in China and internationally.\n        </li>\n<li>\n          In China, 國家藥監局 accepted the biological products license application for 貝伐單抗玻璃體腔內注射液 (TAB014), supporting a potential first-mover position in a wAMD-focused bevacizumab filing.\n        </li>\n<li>\n          For 硫酸阿托品滴眼液 (NVK002), 國家藥監局 accepted the simplified new drug application for the 0.01% dose and accepted the new drug application for the 0.02% dose, keeping both formulations under review as potential growth drivers.\n        </li>\n<li>\n          In the US, FDA approved the new drug investigational application for 環孢素眼用凝膠 to start a Phase III trial, which could strengthen partnering options and broaden the addressable market beyond Greater China.\n        </li>\n<li>\n          Commercial readiness was supported by RMB 959 million in cash and cash equivalents, while loss narrowed to RMB 209 million.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhaoke Ophthalmology Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260325-12067098), on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1587","symbol_name":"半新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL94t3zx:1","article_id":"2622078184","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622078184","pubTimestamp":1774439016,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zhaoke Ophthalmology reported regulatory milestones that could expand its near-term commercial portfolio, led by three flagship assets positioned for large ophthalmology markets in China and internationally.In China, 國家藥監局 accepted the biological products license application for 貝伐單抗玻璃體腔內注射液 , supporting a potential first-mover position in a wAMD-focused bevacizumab filing.In the US, FDA approved the new drug investigational application for 環孢素眼用凝膠 to start a Phase III trial, which could strengthen partnering options and broaden the addressable market beyond Greater China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhaoke Ophthalmology Ltd. published the original content used to generate this news brief via IIS, the Issuer Informat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1587":"次新股","BK1574":"生物医药B类股","BK1583":"高瓴概念","06622":"兆科眼科-B","BK1191":"制药"},"translate_title":"Zhaoke Ophthalmology FY2025; revenue drops to CNY 32 million due to lower one-off license income","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06622":0.9},"content_text":"Zhaoke Ophthalmology FY2025; revenue drops to CNY 32 million due to lower one-off license income\n    \n\n\n          Zhaoke Ophthalmology reported regulatory milestones that could expand its near-term commercial portfolio, led by three flagship assets positioned for large ophthalmology markets in China and internationally.\n        \n\n          In China, 國家藥監局 accepted the biological products license application for 貝伐單抗玻璃體腔內注射液 (TAB014), supporting a potential first-mover position in a wAMD-focused bevacizumab filing.\n        \n\n          For 硫酸阿托品滴眼液 (NVK002), 國家藥監局 accepted the simplified new drug application for the 0.01% dose and accepted the new drug application for the 0.02% dose, keeping both formulations under review as potential growth drivers.\n        \n\n          In the US, FDA approved the new drug investigational application for 環孢素眼用凝膠 to start a Phase III trial, which could strengthen partnering options and broaden the addressable market beyond Greater China.\n        \n\n          Commercial readiness was supported by RMB 959 million in cash and cash equivalents, while loss narrowed to RMB 209 million.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhaoke Ophthalmology Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260325-12067098), on March 25, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}